RE:RE:RE:Company buyout price vs share price.Just one example is Trillium Therapeutics, a Phase 1 company that Pfizer acquired for US $2.3 Billion in 2021.
Pfizer's acquisition price had nothing to do with Trillium offering "de-risked" assets.
https://www.pfizer.com/news/press-release/press-release-detail/pfizer-acquire-trillium-therapeutics-inc
So if ONCY wants a US$14+ Billion acquisition offer, like Karuna Therapeutics is receiving, then going after an Accelerated Approval for pelareorep is just one of the ways.
To have Canadafan offer up his unrelated "home-spun" loser opinion is entirely counter-productive to the direction that ONCY needs to take under the current circumstances.